The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001266358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
22/08/2026
Date registered
Help: Date registered
21/10/2026
Date last updated
Help: Date last updated
21/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
21/10/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A Study to Test the Safety and Effects of VIAL-IL13xTSLP in Patients with Mild-to-Moderate Asthma
Scientific title
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Proof-of-Mechanism of VIAL-IL13xTSLP in Patients with Mild-to-Moderate Asthma
Additional trial identifiers [1] 317813 0
None
Universal Trial Number (UTN)
U1111-1335-2078
Trial acronym
Related trial records
The Phase 1 study (ACTRN12626000876392) in healthy volunteers established the safety, tolerability and pharmacokinetics of VIAL-IL13xTSLP and informed the dose selection for this study in patients with mild-to-moderate asthma.

Health condition
Health condition(s) studied:
Asthma (Mild-to-moderate) 342728 0
Condition category
Condition code
Respiratory 338866 338866 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
VIAL-IL13xTSLP or placebo will be administered subcutaneously to patients with mild-to-moderate asthma in up to two cohorts. Each cohort will evaluate a dose regimen selected from the highest dose exposure level(s) determined to be safe and tolerable in the Phase 1 study in healthy volunteers (ACTRN12626000876392), within the evaluated dose range of 15–1,600 mg. Participants will be randomized in an approximately 4:1 ratio to receive VIAL-IL13xTSLP or placebo.

Cohort 1 will receive 300 mg VIAL-IL13xTSLP or placebo subcutaneously every two weeks (Q2W) for a total of 3 doses. For Cohort 2, the dose level(s), dosing interval, number of administrations (2–3, which may include a loading-and-maintenance schedule informed by Phase 1 safety, pharmacokinetic, and modeling data from healthy volunteers), and route of administration (intravenous or subcutaneous) will be prospectively confirmed following Safety Review Committee (SRC) review before implementation of the cohort.

Adherence: Adherence is assured by on-site administration under direct medical supervision, with all participants followed for safety, pharmacokinetic, and pharmacodynamic assessments through Day 251 post-dose.
Intervention code [1] 334653 0
Treatment: Drugs
Description of the comparator or control
Placebo is supplied as a sterile, solution for injection matched to the final formulation buffer of the active drug product.
Control group
Placebo

Outcomes
Primary outcome [1] 346082 0
Evaluate the safety and tolerability of VIAL-IL13xTSLP as a composite primary outcome.
Timepoint [1] 346082 0
— Adverse Events: Continuously from informed consent through Day 251. — Laboratory Tests: Screening, Days -1, 2, 3, 5, 8, 15, 22, 29, 33, 36, 43, 57, 71, and monthly through Day 251. — Physical Examinations: Full examination at screening, Day 1, and Day 251; symptom-directed examination at Days -1, 2, 3, 5, 8, 15, 22, 29, 33, 36, 43, 57, 71, and 221. — Vital Signs: Screening, Days -1, 1, 2, 3, 5, 8, 15, 22, 29, 33, 36, 43, 57, 71, and monthly through Day 251. — 12-lead ECGs: Screening, Days -1, 1, 2, 3, 5, 8, 15, 22, 29, 33, 36, 43, 57, 71, and monthly through Day 251.
Secondary outcome [1] 464519 0
Characterise the pharmacokinetics (PK) of VIAL-IL13xTSLP, including maximum observed plasma concentration (Cmax), time to maximum plasma concentration (Tmax), area under the plasma concentration-time curve (AUC), half-life (t½), mean residence time (MRT), systemic clearance (CL), and volume of distribution at steady state (Vss).
Timepoint [1] 464519 0
PK samples collected on Day 1 at pre-dose and 8 hours post-dose, then at Days 2, 3, 5, 8, 15, 22, 29, 33, 36, 43, 57, 71, and monthly through Day 251.

Eligibility
Key inclusion criteria
- Documented asthma for at least 12 months
- Fractional Exhaled Nitric Oxide (FeNO) level of at least 25 ppb once during screening and at least 20 ppb at baseline/randomization
- Pre-bronchodilator FEV1 45%–90% predicted, with documented variable or reversible airflow limitation
- No more than 1 rescue inhaler canister per month
- On Short-Acting Beta-Agonist (SABA) alone (ICS-naïve) or stable low-to-medium dose Inhaled Corticosteroid (ICS) (no more than 500 mcg fluticasone equivalent) for at least 3 months
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
- Chronic lung disease (non-asthma)
- Clinically significant viral infection
- Serious/life-threatening asthma exacerbation within 3 months
- Prior biologic targeting IL-4R, IL-4, IL-13, IL-5/IL-5R, TSLP, or IgE within 4 months or 5 half-lives, whichever is longer

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed through central randomisation. Active drug and placebo, identical in appearance, packaging, and labeling, will be identified only by algorithm-assigned vial numbers.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computer-generated randomization sequence will be used.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322357 0
Commercial sector/Industry
Name [1] 322357 0
Vial Australia Pty Ltd
Country [1] 322357 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Vial Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325277 0
None
Name [1] 325277 0
Address [1] 325277 0
Country [1] 325277 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320860 0
Bellberry Human Research Ethics Committee F
Ethics committee address [1] 320860 0
Ethics committee country [1] 320860 0
Australia
Date submitted for ethics approval [1] 320860 0
Approval date [1] 320860 0
19/08/2026
Ethics approval number [1] 320860 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151862 0
Dr Eunic Yuen Kwan Dai
Address 151862 0
Vial Australia Pty Ltd, 428 George Street, WellShare, Level 7, Suite 12, Room 7, Dymocks Building, Sydney CBD, NSW, 2000
Country 151862 0
Australia
Phone 151862 0
+61 417 997 832
Fax 151862 0
Email 151862 0
Contact person for public queries
Name 151863 0
Dr. Glenn Fitzpatrick
Address 151863 0
Vial Australia Pty Ltd, 428 George Street, WellShare, Level 7, Suite 12, Room 7, Dymocks Building, Sydney CBD, NSW, 2000
Country 151863 0
Australia
Phone 151863 0
+61 474 485 209
Fax 151863 0
Email 151863 0
Contact person for scientific queries
Name 151864 0
Dr. Jared Sharp
Address 151864 0
Vial Health Technology, Inc., 1875 Mission Street Ste 103, #200, San Francisco, CA 94103
Country 151864 0
United States of America
Phone 151864 0
+1 415 300 0607
Fax 151864 0
Email 151864 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.